Body fluid BIN1 as a marker of cardiac health
AssigneeThe Regents of the University of California
InventorsRobin Shaw, Ting-Ting Hong
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods involving use of BIN1 protein levels in biological fluid of a subject in evaluating cardiac health of the subject. The method provided herein may be used to predict a risk of a poor outcome in a subject. The methods also find use in evaluating subjects for assessing patients diagnosed with heart failure. These methods are also useful in assessing therapy options and efficacy of treatment in heart failure patients.
Claims10
A method for assessing for presence of non-acute heart failure in a human subject at risk for heart failure, the method comprising:
- measuring a cardiac BIN1 protein level in a blood, serum or plasma sample obtained from the subject, wherein the measuring is performed by contacting the blood, serum or plasma sample with an anti-cardiac BIN1 antibody;
- comparing the cardiac BIN1 protein level to a normal cardiac BIN1 protein level;
- and
- assessing the presence of non-acute heart failure in the subject when the cardiac BIN1 protein level is significantly decreased compared to the normal BIN1 protein level, wherein the normal cardiac BIN1 level is obtained from assaying cardiac BIN1 protein in a blood, serum or plasma sample obtained from a healthy human.
A method of predicting a risk of poor cardiac outcome in a human subject at risk for non-acute heart failure, the method comprising:
- measuring a cardiac BIN1 protein level in a blood, serum or plasma sample obtained from the subject wherein the measuring is performed by contacting the blood, serum or plasma sample with an anti-cardiac BIN1 antibody;
- comparing the cardiac BIN1 protein level to a normal cardiac BIN1 protein level;
- and
- predicting an increased risk of poor outcome when cardiac BIN1 protein level in the blood, serum or plasma sample is significantly decreased compared to the normal cardiac BIN1 protein level,
- wherein the normal cardiac BIN1 level is obtained from assaying cardiac BIN1 protein in a blood, serum or plasma sample obtained from a healthy human.
A method of predicting a risk of cardiac mortality in a human patient diagnosed with chronic heart failure, the method comprising:
- measuring a cardiac BIN1 protein level in a blood, serum or plasma sample obtained from the patient wherein the measuring is performed by contacting the blood, serum or plasma sample with an anti-cardiac BIN1 antibody;
- comparing the cardiac BIN1 protein level to a normal cardiac BIN1 protein level;
- and
- predicting an increased risk of cardiac mortality when the cardiac BIN1 protein level in the blood, serum or plasma sample is significantly decreased compared to the normal cardiac BIN1 protein level,
- wherein the normal cardiac BIN1 level is obtained from assaying cardiac BIN1 protein in a blood, serum or plasma sample obtained from a chronic heart failure human patient.
Dependencies are inferred from the claim text.